Sen­ate com­mit­tee ad­vances bill tar­get­ing Chi­nese man­u­fac­tur­ers as BIO faces at­tack for back­ing WuXi

A Sen­ate com­mit­tee on Wednes­day moved a con­tentious bill for­ward that would pro­hib­it many bio­phar­ma com­pa­nies from us­ing cer­tain for­eign man­u­fac­tur­ing and tri­al ser­vice providers like Chi­na’s WuXi AppTec, re­fer­ring to them as “com­pa­nies of con­cern.”

The Home­land Se­cu­ri­ty and Gov­ern­men­tal Af­fairs Com­mit­tee vot­ed 11-1 to ad­vance the bill, which is part of a wider push from law­mak­ers on both sides of the aisle to lim­it Chi­na’s in­flu­ence in the US. That think­ing is gain­ing po­lit­i­cal steam, but in­dus­try has said that these laws would al­so make busi­ness dif­fi­cult for a large num­ber of bio­phar­ma com­pa­nies that re­ly on Chi­nese com­pa­nies for clin­i­cal re­search and man­u­fac­tur­ing sup­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER